abstract |
The present invention is directed to compounds that are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, which involve neurological and psychiatric disorders associated with glutamate dysfunction and metabotropic glutamate receptors. Useful in the treatment and prevention of disease. The present invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention and treatment of diseases involving metabotropic glutamate receptors. |